{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:58:18Z","timestamp":1757617098810,"version":"3.44.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12288-024-01881-0","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T22:10:10Z","timestamp":1727215810000},"page":"665-669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inotuzumab Ozogamicin in Indian Patients with B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"41","author":[{"given":"Pronamee","family":"Borah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Capoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-8588","authenticated-orcid":false,"given":"Rahul","family":"Naithani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"issue":"1","key":"1881_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cncr.27617","volume":"119","author":"W Stock","year":"2013","unstructured":"Stock W, Johnson JL, Stone RM et al (2013) Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer 119(1):90\u201398","journal-title":"Cancer"},{"issue":"8","key":"1881_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ajh.24419","volume":"91","author":"ME Rytting","year":"2016","unstructured":"Rytting ME, Jabbour EJ, Jorgensen JL et al (2016) Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol 91(8):819\u2013823","journal-title":"Am J Hematol"},{"issue":"1","key":"1881_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12288-022-01541-1","volume":"39","author":"R Chadha","year":"2023","unstructured":"Chadha R, Udayakumar DS, Sangwan S, Gore A, Jha B, Goel S, Mathur N, Rastogi N, Dixit R, Sood N, Yadav SP, Saxena R (2023) Cytogenetic risk stratification of B-Acute lymphoblastic leukemia and its correlation with other prognostic factors. Indian J Hematol Blood Transfus 39(1):141\u2013145","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"1881_CR4","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.clml.2020.08.023","volume":"21","author":"VS Radhakrishnan","year":"2021","unstructured":"Radhakrishnan VS, Agrawal N, Bagal B, Patel I (2021) Systematic review of the Burden and Treatment Patterns of Adult and adolescent Acute Lymphoblastic Leukemia in India: comprehending the challenges in an Emerging Economy. Clin Lymphoma Myeloma Leuk 21(1):e85\u2013e98","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1881_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12288-023-01641-6","volume":"40","author":"H Menon","year":"2024","unstructured":"Menon H, Singh PK, Bagal B, Dolai T, Jain A, Chaudhri A (2024) Minimal residual disease in the management of B-Cell Acute Lymphoblastic Leukemia: a systematic review of studies from Indian settings. Indian J Hematol Blood Transfus 40(1):1\u201311","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"8","key":"1881_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, G\u00f6kbuget N, O\u2019Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS (2016) Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med 375(8):740\u2013753","journal-title":"N Engl J Med"},{"issue":"6","key":"1881_CR7","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM (2023) Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433\u2013e444","journal-title":"Lancet Haematol"},{"key":"1881_CR8","doi-asserted-by":"publisher","unstructured":"Mohan V, Jain S, Naithani R (2024) Low dose Venetoclax, Bortezomib, Inotuzumab, Rituximab, and Dexamethasone (LoVe-BIRD) in a child with Relapsed\/Refractory B-cell Acute Lymphoblastic Leukemia with TP53 mutation. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.31152 (in press)","DOI":"10.1002\/pbc.31152"},{"key":"1881_CR9","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1002\/cncr.28136","volume":"119","author":"H Kantarjian","year":"2013","unstructured":"Kantarjian H, Thomas D, Jorgensen J et al (2013) Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119:2728\u20132736","journal-title":"Cancer"},{"key":"1881_CR10","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","volume":"1","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo DJ, Stock W, Stein AS et al (2017) Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study. Blood Adv 1:1167\u20131180","journal-title":"Blood Adv"},{"key":"1881_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","volume":"53","author":"P Kebriaei","year":"2018","unstructured":"Kebriaei P, Cutler C, de Lima M et al (2018) Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transpl 53:449\u2013456","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"1881_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-024-01552-7","volume":"17","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jain N, Kantarjian H (2024) Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions. J Hematol Oncol 17(1):32. https:\/\/doi.org\/10.1186\/s13045-024-01552-7","journal-title":"J Hematol Oncol"},{"key":"1881_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","volume":"13","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, Thomas D, Jorgensen J et al (2012) Inotuzumab ozogamicin, an anti-CD22\u2013calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13:403\u2013411","journal-title":"Lancet Oncol"},{"key":"1881_CR14","doi-asserted-by":"crossref","unstructured":"Muffly L (2023) ALLIANCE A042001: a Randomized Clinical Trial to determine whether inotuzumab + Mini-HyperCVD will replace HyperCVAD as Frontline Treatment in older adult ALL. Hematologist ; 20","DOI":"10.1182\/hem.V20.2.202326"},{"issue":"3","key":"1881_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.23.00546","volume":"42","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N et al (2024) Inotuzumab Ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-Precursor ALL. J Clin Oncol 42(3):273\u2013282. https:\/\/doi.org\/10.1200\/JCO.23.00546","journal-title":"J Clin Oncol"},{"key":"1881_CR16","doi-asserted-by":"publisher","unstructured":"Wieduwilt MJ, Yin J, Kour O et al (2023) Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703. Hemasphere. ;7(Suppl):e08838b7. https:\/\/doi.org\/10.1097\/01.HS9.0000967380.08838.b7","DOI":"10.1097\/01.HS9.0000967380.08838.b7"},{"issue":"02","key":"1881_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1055\/s-0041-1731860","volume":"42","author":"K Radhakrishnan Vivek, Modak","year":"2021","unstructured":"Radhakrishnan Vivek, Modak K, Bhave S, Kumar J, Roychowdhury M, Ghosh M et al (2021) Inotuzumab Ozogamicin Monotherapy as an Outpatient Salvage Treatment in Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia: compassionate Access. Indian J Med Paediatr Oncol 42(02):199\u2013203 doi \u2013 10.1055\/s-0041-1731860","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"11","key":"1881_CR18","first-page":"911","volume":"44","author":"LL An","year":"2023","unstructured":"An LL, Zhao DF, Hou RF, Guan HH, Yan H, Lin YH, Tong CR, Wu T, Liu SY (2023) Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed\/refractory B-cell acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi 44(11):911\u2013916","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"5","key":"1881_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood.2023022330","volume":"143","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H (2024) Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 143(5):417\u2013421","journal-title":"Blood"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-024-01881-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:11:25Z","timestamp":1757117485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-024-01881-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1881"],"URL":"https:\/\/doi.org\/10.1007\/s12288-024-01881-0","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"type":"print","value":"0971-4502"},{"type":"electronic","value":"0974-0449"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by institutional ethics committee (PHPL\/PHIEC-COMM\/2024\/003).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"PB declares that she has no conflict of interest. VM declares that he has no conflict of interest. SJ declares that he has no conflict of interest. VC declares that he has no conflict of interest. RN declares that he has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}